

Issue Tracker



Together,
there's
something
science
can do.

Issue Tracker 2024/003
June 5, 2024

[Pharmaceutical Shortages in UK reach record high:](#) The number of pharmaceutical shortages has doubled since January 2022, affecting antibiotics, treatments for diabetes, attention deficit hyperactivity disorder and hormone replacement therapy. While pharmaceutical shortages appear to be a worldwide phenomenon, the increased regulatory delays caused by Brexit have exacerbated the shortages in the UK.

[Teva Pharmaceuticals Found Liable for Improper FDA Listing:](#) Teva had improperly listed multiple patents relating to asthma inhalers in the FDA's Orange Book, delaying competitors ability to enter the market. Accordingly, the District Court for New Jersey ordered that these patents be delisted. While this case was brought by a competitor, it follows [increased enforcement of improper Orange Book listings by the FTC.](#)

[Repurposed autoimmune disease drug found to alleviate symptoms of a rare genetic disease:](#) Researchers at the National Institutes of Health's National Institute of Allergy and Infectious Diseases have shown that a drug approved for certain autoimmune diseases and cancers can alleviate symptoms of autoimmune polyendocrine syndrome type 1 (APS-1), a rare genetic syndrome that is life-threatening.

[Sanofi, Formation Bio and OpenAI collaborate to accelerate drug development:](#) The collaboration seeks to develop pharma-specific AI models. Sanofi will contribute proprietary data and Formation Bio will contribute engineering resources, its experience in pharma and AI, and its tech-driven development platform. OpenAI will be contributing access to cutting-edge AI capabilities.

[Sengenics Corporation and Duke Health to collaborate on metastatic colorectal cancer \(mCRC\) treatment:](#) The collaboration will explore the immune system's response to immunotherapy to discover autoantibody biomarkers related to drug efficacy, resistance, and toxicity. This will be completed by leveraging Sengenics' KREX technology. MCRC is a significant challenge in oncology due to its 5-year survival rate of 14%.